| Ankylosing spondylitis
Acthar vs Vimovo
Side-by-side clinical, coverage, and cost comparison for ankylosing spondylitis.Deep comparison between: Acthar vs Vimovo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVimovo has a higher rate of injection site reactions vs Acthar based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vimovo but not Acthar, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Acthar
Vimovo
At A Glance
IM or SC injection
Corticotropin analog
Oral
Twice daily
NSAID + Proton Pump Inhibitor
Indications
- Infantile Spasm
- Multiple Sclerosis
- Arthritis, Psoriatic
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Lupus Erythematosus, Systemic
- Dermatomyositis
- Polymyositis
- Erythema Multiforme
- Stevens-Johnson Syndrome
- Serum Sickness
- Keratitis
- Iritis
- Iridocyclitis
- Uveitis, Posterior
- Choroiditis
- Optic Neuritis
- Chorioretinitis
- Sarcoidosis
- Nephrotic Syndrome
- Degenerative polyarthritis
- Rheumatoid Arthritis
- Ankylosing spondylitis
- Juvenile arthritis
Dosing
Infantile Spasm 150 U/m2/day IM divided into 75 U/m2 twice daily for 2 weeks, then taper over 2 weeks; Acthar Gel vial only -- do not use the pre-filled SelfJect injector.
Multiple Sclerosis 80-120 units IM or SC daily for 2-3 weeks for acute exacerbations; taper as needed.
Arthritis, Psoriatic, Rheumatoid Arthritis, Ankylosing spondylitis, Lupus Erythematosus, Systemic, Dermatomyositis, Polymyositis, Erythema Multiforme, Stevens-Johnson Syndrome, Serum Sickness, Keratitis, Iritis, Iridocyclitis, Uveitis, Posterior, Choroiditis, Optic Neuritis, Chorioretinitis, Sarcoidosis, Nephrotic Syndrome 40-80 units IM or SC every 24-72 hours; individualize dosing based on disease severity and patient response; taper dose upon discontinuation.
Degenerative polyarthritis, Rheumatoid Arthritis, Ankylosing spondylitis Adults: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily, taken orally at least 30 minutes before meals; use lowest effective naproxen dose for shortest duration.
Juvenile arthritis Adolescents >=12 years and >50 kg: one tablet (375 mg or 500 mg naproxen/20 mg esomeprazole) twice daily; 38 kg to <50 kg: one tablet (375 mg naproxen/20 mg esomeprazole) twice daily, taken at least 30 minutes before meals.
Contraindications
- Intravenous administration
- Use in infants under 2 years of age with suspected congenital infections
- Concomitant live or live-attenuated vaccines during immunosuppressive doses of Acthar Gel
- Scleroderma
- Osteoporosis
- Systemic fungal infections
- Ocular herpes simplex
- Recent surgery
- History of or presence of peptic ulcer
- Congestive heart failure
- Uncontrolled hypertension
- Primary adrenocortical insufficiency
- Adrenocortical hyperfunction
- Sensitivity to proteins of porcine origin
- Known hypersensitivity to naproxen, esomeprazole magnesium, substituted benzimidazoles, or any components of the drug product, including omeprazole
- History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
- Coronary artery bypass graft (CABG) surgery
- Concomitant use of rilpivirine-containing products
Adverse Reactions
Most common (>=5%) Infections, convulsions, hypertension, irritability, pyrexia (reported in infantile spasm trials at recommended dose)
Serious Cushing's syndrome, adrenal insufficiency upon withdrawal, elevated blood pressure, salt and water retention, hypokalemia, gastrointestinal perforation and bleeding, behavioral and mood disturbances, ophthalmic effects, decreased bone density, negative effects on growth and physical development
Postmarketing Anaphylaxis, necrotizing angitis, pancreatitis, intracranial hemorrhage, subdural hematoma, reversible brain shrinkage, vertebral compression fractures, insomnia, injection site reactions
Most common (>2%) Gastritis, diarrhea, upper respiratory tract infection, flatulence, headache, urinary tract infection, dysgeusia
Serious Cardiovascular thrombotic events, GI bleeding/ulceration/perforation, hepatotoxicity, hypertension, heart failure and edema, renal toxicity and hyperkalemia, anaphylactic reactions, serious skin reactions, DRESS, fetal toxicity, hematologic toxicity
Postmarketing Gait disturbance, abdominal distension, hematochezia, joint swelling, muscle spasms, renal tubular necrosis, angioedema, aplastic anemia, hepatitis, Stevens-Johnson Syndrome, toxic epidermal necrolysis, hypomagnesemia, cutaneous lupus erythematosus
Pharmacology
Repository corticotropin (ACTH) analog that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and weak androgens; also reported to bind melanocortin receptors, with the trophic effects on the adrenal cortex appearing to be mediated by cyclic AMP.
VIMOVO is a fixed-dose combination of naproxen, an NSAID that inhibits cyclooxygenase (COX-1 and COX-2) to reduce prostaglandin synthesis with analgesic, anti-inflammatory, and antipyretic effects, and esomeprazole magnesium, a proton pump inhibitor that suppresses gastric acid secretion by inhibiting the H+/K+-ATPase in the gastric parietal cell to reduce naproxen-associated gastric ulcer risk.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Acthar
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (1/12) · Qty limit (0/12)
Vimovo
- Covered on 5 commercial plans
- PA (6/12) · Step Therapy (1/12) · Qty limit (1/12)
UnitedHealthcare
Acthar
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Vimovo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Acthar
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (2/3)
Vimovo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Acthar.
No savings programs available for Vimovo.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
ActharView full Acthar profile
VimovoView full Vimovo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.